Waters Biosciences brings the former BD flow portfolio to ICCS 2026 under its new division

Summary

ICCS 2026 is the first ICCS meeting after Waters completed its February 2026 combination with BD's Biosciences & Diagnostic Solutions businesses. Waters Biosciences is now presenting the flow cytometry portfolio as a connected stack spanning routine clinical flow, spectral analysis, imaging flow, sample preparation, reagents and software.

The evidence

Waters completed its combination with BD's Biosciences & Diagnostic Solutions businesses on 9 February 2026 and created a Waters Biosciences division containing the former BD Biosciences portfolio.

At ICCS 2026, Waters Biosciences is presenting a connected flow cytometry stack that includes FACSLyric and FACSDuet for routine workflows, FACSDiscover A7 for higher-dimensional spectral analysis, FACSDiscover A8 with CellView imaging, Horizon reagents, Cytognos MRD research workflows, Infinicyt and FlowJo software.

CFCM explainer — portfolio architecture

Routine clinical workflow → spectral analysis → imaging flow → software/data analysis.

Source/credit: CFCM market-architecture explainer based on the current Waters Biosciences ICCS 2026 portfolio page, checked 4 October 2026. Alt text: four-stage diagram showing routine clinical flow, spectral analysis, imaging flow and downstream software under Waters Biosciences.

This is a company and portfolio signal, not evidence that every named product has the same regulatory status or intended use.

Interpretation and limitations

Conference positioning such as a connected vision for clinical flow cytometry is corporate messaging, not independent evidence of analytical superiority. Product regulatory status remains product- and jurisdiction-specific. The ICCS page mixes routine clinical systems with research-use technologies, so CFCM does not transfer clinical status from one product to another.

What this means for laboratories

For laboratories and competitors, the important market change is organizational: one of the largest installed flow-cytometry portfolios is now being presented as part of Waters Biosciences rather than as a standalone BD Biosciences business. That can affect future software integration, portfolio bundling, service strategy and the way laboratories compare complete ecosystems instead of individual cytometers.

Source Date

Event date

October 4, 2026

Commercial Regulatory Status

Waters completed the combination with BD's Biosciences & Diagnostic Solutions businesses on 9 February 2026. ICCS 2026 materials present the flow portfolio under Waters Biosciences. No new CE-IVD or FDA authorization is inferred from conference branding.

Primary source

Read the source →

An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.

Editor and independence disclosure →

CFCM WEEKLY · EVERY SUNDAY

The science behind the signal, in your inbox.

Get evidence-led clinical flow cytometry news, original conference posters, figures from published papers, practical learning pills, an advanced quiz and the story of one CD marker each week. Free. No spam.

Get CFCM Weekly →

Complete the form and confirm the email we send you. Unsubscribe any time. Privacy policy.